Irish Biotechnology Company selected for prestigious health tech accelerator programme
Valitacell, an Irish biotechnology SME, has been selected by as one of 11 high potential global start-ups to join the prestigious health tech accelerator programme Startup Creasphere. The Startup Creasphere innovation programme matches global pharmaceutical partners including Roche, Sanofi and Lonza with the World’s most innovative and disruptive health tech start-ups.
The global healthcare giant Lonza has chosen to collaborate with Valitacell as their chosen high potential start up for the 3-month programme.
Commenting on the partnership, Dr. Stephanie Davies, Head of Cell Therapy at Valitacell, said: “Valitacell is delighted to have been chosen by Lonza for this 3-month accelerator programme and we look forward to working with Lonza to transform healthcare together.”
Established in 2014, Valitacell is an award winning, Irish SME that produces innovative products and technologies for the biopharmaceutical industry. Valitacell’s products enable biopharmaceutical companies bring drugs to the market quicker, cheaper and with greater regulatory confidence.
Founded in Switzerland in 1897, Lonza is a leading global provider of integrated healthcare solutions employing 15,500 employees across 35 countries and generating over €5.5 billion annually.
